Log In
BCIQ
Print this Print this
 

Biosimilar adalimumab (BAX 923, M923)

  Manage Alerts
Collapse Summary General Information
Company Momenta Pharmaceuticals Inc.
DescriptionBiosimilar of adalimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$452.0M

$33.0M

$391.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

$452.0M

$33.0M

$391.0M

Get a free BioCentury trial today